Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | +20.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.07 | N/A | +20.45% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future developments. They focused on the importance of their clinical pipeline but did not provide specific revenue guidance.
Management highlighted ongoing commitment to pipeline development.
They emphasized the importance of upcoming clinical trials.
No specific revenue guidance was provided, indicating uncertainty.
Nektar Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted negatively, declining by 0.27%. The lack of revenue figures and guidance may have contributed to investor caution moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 3, 2010